Overweight Clinical Trials in Austin, Texas

14 studies are recruiting for overweight in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

    Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AURORA-2 Clinical Site, Austin, Texas
    Locations
    135 in total
    Run by
    Ascletis Pharma (China) Co., Limited

    See if you can join NCT07743450 on ClinicalTrials.gov

  2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

    Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AURORA-1 Clinical Site, Austin, Texas
    Locations
    122 in total
    Run by
    Ascletis Pharma (China) Co., Limited

    See if you can join NCT07743463 on ClinicalTrials.gov

  3. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

    This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

    Stage
    Phase 3
    Ages
    18 to 79
    Site
    ACCOMPLISH-2 Research Site, Austin, Texas
    Locations
    74 in total
    Run by
    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654374 on ClinicalTrials.gov

  4. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    IMA Clinical Research Austin, Austin, Texas
    Locations
    56 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06143956 on ClinicalTrials.gov

  5. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    IMA Clinical Research Austin, Austin, Texas
    Locations
    157 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07282600 on ClinicalTrials.gov

  6. A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

    The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    FutureSearch Trials of Neurology, Austin, Texas
    Locations
    115 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07369011 on ClinicalTrials.gov

  7. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    Stage
    Phase 3
    Ages
    45 to 99
    Site
    Austin Heart, Austin, Texas
    Locations
    783 in total
    Run by
    Amgen

    See if you can join NCT07037433 on ClinicalTrials.gov

  8. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Elligo Clinical Research Center, Austin, Texas
    Locations
    37 in total
    Run by
    Amgen

    See if you can join NCT07684144 on ClinicalTrials.gov

  9. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Elligo Clinical Research Center, Austin, Texas
    Locations
    87 in total
    Run by
    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

  10. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

    Stage
    Phase 3
    Ages
    6 to 17
    Site
    Dell Children's Medical Center - PIN, Austin, Texas
    Locations
    117 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06672549 on ClinicalTrials.gov

  11. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

    Stage
    Phase 3
    Ages
    18 to 79
    Site
    ACCOMPLISH-1 Research Site, Austin, Texas
    Locations
    71 in total
    Run by
    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654361 on ClinicalTrials.gov

  12. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    IMA Clinical Research Austin, Austin, Texas
    Locations
    40 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07589608 on ClinicalTrials.gov

  13. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

    The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Elligo Clin Res Centre, Austin, Texas
    Locations
    11 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07607587 on ClinicalTrials.gov

  14. Semaglutide for Post-Smoking Cessation Weight Management

    This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    The University of Texas at Austin, Austin, Texas
    Locations
    2 in total
    Run by
    The University of Texas Health Science Center, Houston

    See if you can join NCT06173778 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.